Halozyme Therapeutics director Jeffrey Henderson sells $500,060 in stock By Investing.com

SAN DIEGO – Jeffrey William Henderson, director Halozyme Therapeutics Inc. (NASDAQ:), recently sold 10,000 shares of the company’s common stock.The sale was part of a prearranged Rule 10b5-1 trading plan that Henderson adopted on September 17, 2024. The transaction takes place as InvestingPro: data shows that Halozym maintains a perfect Piotroski score of 9, indicating strong financial health.

The stock was sold at a weighted average price of $50.00, ranging from $50.11 to $50.11.After this sale, Henderson directly owns 43,611 shares of Halozyme stock, with a current share price of $51.19 InvestingPro: suggest the stock is in overbought territory, although analysis suggests the company remains undervalued based on fair value calculations.

The deal is part of a broader strategy for executives to manage their holdings while complying with insider trading regulations.Halozyme Therapeutics, based in San Diego, specializes in the development and commercialization of biologics.The company is now valued at 6.5 billion dollars, boasts an impressive 74% gross profit margin and a strong return on equity Discover about HALO 10+ additional exclusive insights InvestingPro:The comprehensive research report of

In other recent news, Halozyme Therapeutics has seen significant progress with the recent FDA approval of the subcutaneous version of Bristol-Myers Squibb’s (NYSE: ) PD-1 inhibitor OPDIVO Qvantig, which uses Halozyme’s ENHANZE technology. The technology allows for faster and easier medication administration, which offers convenience and time-saving benefits is a buy rating on Halozyme.

In addition, Halozyme’s third-quarter revenue was $290 million, driven primarily by royalty-based revenue from its ENHANZE technology.Net income was also flat at $137 million, or $1.05 per diluted share. Following these results, Halozyme’s full-year 2024 revenue guidance was revised upward to $970 million. $1.02 billion, expecting an increase in royalty revenues.

However, Halozyme withdrew its takeover offer Evotec AG (ETR.), a European drug discovery and development company, after meeting resistance from Evotec’s management.However, HC Wainwright maintained its Buy rating on Halozyme, viewing the result as Neutral.Piper Sandler also adjusted Halozyme price target on its stock to $52.00, maintaining a neutral rating.These are the latest developments on Halozyme Therapeutics.

This article is powered by AI and has been reviewed by an editor. See our T&C for more information.